Pharmacy Grand Rounds
CaLLing Targeted Therapies: Advancements in Chronic Lymphocytic Leukemia

• ACPE Universal Activity Number (UAN): JA0000238-0000-20-028-L01-P
• Session Type: Knowledge-based
• CE Credits: A maximum of 0.75 contact hour (0.075 CEU) for the following: 
  • AAPA Category 1 CME Credits
  • ACPE
  • AMA PRA Category 1 Credits™
  • ANCC

• Session Fee: Free for Mayo Clinic staff

SESSION LOCATIONS

Live Session: (11:00am - 11:45am CST)

Until future notice, learners must watch Pharmacy Grand Rounds live via the web by going to the Video Exchange and selecting “Pharmacy Grand Rounds” in the “Streaming Now” section.

Participants may attend by viewing: Live Webcast
Video Recording - access two weeks after session date

COURSE DESCRIPTION

Over the past few years, management of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted oral agents, including Bruton tyrosine kinase inhibitors, such as ibrutinib and acalabrutinib, and the BCL-2 inhibitor venetoclax. These therapies have unique toxicity profiles, and they have significantly improved patient outcomes and survival, even in high-risk disease. In this presentation, I will review the diagnosis and management of CLL, discuss the role of targeted therapies as first line options, and provide an overview of important clinical considerations and adverse effects associated with the use of these targeted therapeutic agents.

At the conclusion of this knowledge-based CE session, participants should be able to:

1. Review chronic lymphocytic leukemia diagnosis and historical treatment options
2. Describe the pharmacology of Bruton tyrosine kinase inhibitors and venetoclax
3. Discuss the use of targeted agents as first line therapy for chronic lymphocytic leukemia

Session Announcement

Session Slides

FACULTY INFORMATION

Mikhaila L. Rice, PharmD
PGY2 Oncology Pharmacy Resident
Mayo Clinic Hospital - Rochester, MN

Mikhaila received a Doctor of Pharmacy degree from the University of Pittsburgh School of Pharmacy in Pittsburgh, PA.  She completed a PGY1 Pharmacy Residency at Mayo Clinic Hospital-Rochester, and is currently a PGY2 Oncology Pharmacy Resident at Mayo Clinic Hospital-Rochester with practice interests in hematology, oncology, immunology, and infectious disease. 

DISCLOSURE STATEMENTS

As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program:

The faculty report the following relationships:

• Mikhaila L. Rice, PharmD
  • Declares no financial relationships pertinent to this session
  • Declares off-label use of devices and medications will be discussed during this presentation, including:
    • Acalabrutinib
    • Ibrutinib
    • Venetoclax

Course Director and Planning Committee Members declare no relevant financial relationship(s) pertinent to this session.  Members include:

• Brenda Amaris
• Mary Ellen Cordes, MS, APRN, CNC, NE-BC
• Michael Huckabee, MPAS, PA-C, PhD
• Wayne (Nick) Nicholson, MD, PharmD, BCPS
• Garrett Schramm, PharmD, BCPS
• Lee Skrupky, PharmD, BCPS